Asep Inc. signs Letter of Intent for joint venture with Bahrain-based Seaspring W.L.L. for regulatory approval and commercialization of sepsis diagnosis technology

January 6, 2023

Asep Medical Holdings Inc. (Asep Inc.) is delighted to announce the recent signing of a Letter of Intent (LOI) for a joint venture between Asep Inc. and Seaspring W.L.L (Seaspring). The joint venture will be owned 50/50 between Asep Inc. and Seaspring pursuant to a definitive agreement. As per the terms of the LOI that was signed by both parties on December 11, 2022 in Bahrain, Seaspring will contribute the capital required by the joint venture to conduct its business operations while Asep Inc. will provide the licensing rights for use of the technology in the Kingdom of Bahrain and the Middle East and North Africa (MENA) region.

Biotricity, Healthcare

Biotricity files FDA 510(k) for a new form factor of its Biotres Cardiac Monitoring Device to expand its revenue growth

December 12, 2022

Biotricity Inc. (Biotricity) today announced that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a new form factor of its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.

Cybersecurity, Wedge Networks

Wedge Networks to participate in the upcoming Arab International Cybersecurity Summit (AICS)

November 24, 2022

Wedge Networks Inc. (Wedge) announces its participation as a silver sponsor and exhibitor in the upcoming Arab International Cybersecurity Summit (AICS) on December 6 – 8, 2022, at Exhibition World Bahrain. Wedge will exhibit at the summit to provide onsite live demos and exchange knowledge and ideas with industry peers.

Biotricity, News

Biotricity surpasses $10 million in annual revenue run rate

November 21, 2022

Biotricity Inc. (Biotricity) today announced it has surpassed $10 million in annual revenue run rate. “With strong revenue growth each quarter, our scale and market reach increases every day. I am committed to continuing to drive growth and realize our potential,” says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq.

Biotricity, News

Biotricity signs Distribution Agreement to expand access for its Cardiac Monitoring Solutions

November 16, 2022

Biotricity Inc. (Biotricity) has signed a distribution agreement with one of the Top 10 US medical device distributors to distribute its cardiac monitoring solutions, Bioflux and Biotres. With the commercialization of its Bioflux and Biotres products, Biotricity has increased its total addressable market from $1 billion to approximately $6 billion.

Biotricity, Financial Results

Biotricity reports financial results for Fiscal 2023 Second Quarter

November 14, 2022

Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.

In the News